A novel steroidal inhibitor of estrogen-related receptor alpha (ERR alpha).
The orphan nuclear receptor estrogen-related receptor alpha (ERRalpha) has been implicated in the development of various human malignancies, including breast, prostate, ovary, and colon cancer. ERRalpha, bound to a co-activator protein (e.g., peroxisome proliferator receptor gamma co-activator-1alpha, PGC-1alpha), regulates cellular energy metabolism by activating transcription of genes involved in various metabolic processes, such as mitochondrial genesis, oxidative phosphorylation, and fatty acid oxidation. Accumulating evidence suggests that ERRalpha is a novel target for solid tumor therapy, conceivably through effects on the regulation of tumor cell energy metabolism associated with energy stress within solid tumor microenvironments. This report describes a novel steroidal antiestrogen (SR16388) that binds selectively to ERRalpha, but not to ERRbeta or ERRgamma, as determined using a time-resolved fluorescence resonance energy transfer assay. SR16388 potently inhibits ERRalpha's transcriptional activity in reporter gene assays, and prevents endogenous PGC-1alpha and ERRalpha from being recruited to the promoters or enhancers of target genes. Representative in vivo results show that SR16388 inhibited the growth of human prostate tumor xenografts in nude mice as a single agent at 30mg/kg given once daily and 100mg/kg given once weekly. In a combination study, SR16388 (10mg/kg, once daily) and paclitaxel (7.5mg/kg, twice weekly) inhibited the growth of prostate tumor xenografts in nude mice by 61% compared to untreated xenograft tumors. SR16388 also inhibited the proliferation of diverse human tumor cell lines after a 24-h exposure to the compound. SR16388 thus has utility both as an experimental antitumor agent and as a chemical probe of ERRalpha biology.
Biosciences Division, SRI International, 333 Ravenswood Ave., Menlo Park, CA 94025, United States. sarah.duellman@sri.com
Sarah J
SJ
Duellman
Joy M
JM
Calaoagan
Barbara G
BG
Sato
Richard
R
Fine
Boris
B
Klebansky
Wan-Ru
WR
Chao
Peter
P
Hobbs
Nathan
N
Collins
Lidia
L
Sambucetti
Keith R
KR
Laderoute
D000818:Animals; D045744:Cell Line, Tumor; D018360:Crystallography, X-Ray; D004958:Estradiol / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000737:chemistry* / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism; D013256:Steroids / Q000737:chemistry / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays / Q000379:methods; D000097983:ERRalpha Estrogen-Related Receptor
D004958:Estradiol; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013256:Steroids; D000097983:ERRalpha Estrogen-Related Receptor; C551406:21-(2-(N,N-dimethylamino)ethyl)oxy-7a-methyl-19-norpregna-1,3,5(10),17(20)-tetraen-3-ol